Organization
Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France
2 abstracts
Abstract
A NOVEL COMPOSITE ENDPOINT INCLUDING LOW PERIPHERAL JOINT DISEASE ACTIVITY STATE AND CLEAR/ALMOST CLEAR SKIN IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POST HOC ANALYSES OF 2 PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIESOrg: Janssen MEA, Dubai Healthcare City, Dubai, United Arab Emirates, Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States of America, JSS Medical Research, Inc, Montreal, Quebec, Canada, Nantel Medsci Consult, Montreal, Quebec, Canada, Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France,
Abstract
BASELINE CHARACTERISTICS OF REAL-WORLD PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB OR IL-17 INHIBITORS: RESULTS FROM THE ONGOING MULTINATIONAL PSABIOND STUDYOrg: Janssen MEA, Dubai Healthcare City, Dubai, United Arab Emirates, JSS Medical Research, IQVIA, Amsterdam, Netherlands, Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France,